GLP-1/Tirzepatide/Retatrutide/orals/next-gen CV benefit depends on continuous use; rebound risks+triple agonists P3/T1D expansion+WHO obesity chronic+India access/NICE+deprescribing
Key Questions
What cardiovascular benefits did tirzepatide show in SURPASS-CVOT?
Tirzepatide demonstrated superior cardiorenal outcomes in SURPASS-CVOT. Continuous use is key to maintaining these benefits, with risks of rebound upon discontinuation.
What weight loss results were seen with retatrutide and CagriSema?
Retatrutide achieved 29% weight loss in Phase 3 trials, while CagriSema reached 20%. These triple agonists are expanding into Type 1 diabetes and obesity management.
What is the status of oral GLP-1 agonists like orforglipron?
Oral Wegovy and orforglipron offer food-flexible dosing with FDA availability. They address adherence challenges in obesity treatment.
What did NICE decide on semaglutide for cardiovascular risk?
NICE approved semaglutide for reducing major adverse cardiovascular events in overweight or obese patients with CVD, despite cost concerns in trials like SELECT.
What challenges exist with GLP-1 access in India?
Semaglutide is cheap and accessible in India but faces issues like fakes and misuse. WHO emphasizes obesity as chronic, pushing for equity and policy support.
SURPASS-CVOT tirzepatide superior cardiorenal; VA gaps lose MACE; T1D risks; retatrutide P3 29%WL + CagriSema 20%; oral Wegovy pill avail + orforglipron FDA food-flex; biweekly de-escal 88% hold wt w/exercise; WHO equity; India fakes/misuse; NICE SELECT cost hit; OHSU cov loss DM spikes; ASCO GI GLP-1 CRC cut; curcumin inflam cut. Adherence/orals/policy.